With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

GUBamy is part of the investigational amylin field, a burgeoning landscape that includes Novo Nordisk’s CagriSema, a ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...